Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D; on the behalf of CETLAM Group. Díaz-Santa J, et al. Among authors: vives s. Leukemia. 2020 Nov;34(11):2925-2933. doi: 10.1038/s41375-020-0784-2. Epub 2020 Mar 9. Leukemia. 2020. PMID: 32152464
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D; “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group). Díaz-Santa J, et al. Among authors: vives s. Eur J Haematol. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. Epub 2022 Sep 16. Eur J Haematol. 2022. PMID: 36063368
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Martínez-Cuadrón D, Montesinos P, Oriol A, Salamero O, Vidriales B, Bergua J, Herrera P, Vives S, Sanz J, Carpio C, Rodríguez-Veiga R, Moscardó F, Sanz MA. Martínez-Cuadrón D, et al. Among authors: vives s. Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1. Ann Hematol. 2014. PMID: 24081577 Clinical Trial.
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group. Oriol A, et al. Among authors: vives s. Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145276 Free PMC article.
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.
Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM. Genescà E, et al. Among authors: vives s. J Hematol Oncol. 2018 Jul 24;11(1):96. doi: 10.1186/s13045-018-0639-8. J Hematol Oncol. 2018. PMID: 30041662 Free PMC article.
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C, Ayala R, Bilbao-Sieyro C, Chillón MC, Larráyoz MJ, Soria E, Aparicio-Pérez C, Bergua JM, Bernal T, Gil C, Tormo M, Algarra L, Alonso-Domínguez JM, Rodriguez-Arbolí E, Martínez-Sanchez P, Oliva A, Colorado-Araujo AM, Rodríguez-Medina C, Vives S, Hermosín L, Martínez-López J, García-Sanz R, Pérez-Simón JA, Calasanz MJ, Gómez-Casares MT, Barragán E, Sánchez-García J J, Montesinos P. De la Torre EP, et al. Among authors: vives s. Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2023.284601. Online ahead of print. Haematologica. 2024. PMID: 38634126 Free article.
Identification of novel NUP98 fusion partners and co-mutations in Acute Myeloid Leukemia: an adult cohort study.
Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M. Heald JS, et al. Among authors: vives s. Blood Adv. 2024 Mar 27:bloodadvances.2023012479. doi: 10.1182/bloodadvances.2023012479. Online ahead of print. Blood Adv. 2024. PMID: 38536941 No abstract available.
Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
Velasco-Hernandez T, Trincado JL, Vinyoles M, Closa A, Martínez-Moreno A, Gutiérrez-Agüera F, Molina O, Rodríguez-Cortez VC, Ximeno-Parpal P, Fernández-Fuentes N, Petazzi P, Beneyto-Calabuig S, Velten L, Romecin P, Casquero R, Abollo-Jiménez F, de la Guardia RD, Lorden P, Bataller A, Lapillonne H, Stam RW, Vives S, Torrebadell M, Fuster JL, Bueno C, Sarry JE, Eyras E, Heyn H, Menéndez P. Velasco-Hernandez T, et al. Among authors: vives s. Hemasphere. 2024 Feb 26;8(2):e45. doi: 10.1002/hem3.45. eCollection 2024 Feb. Hemasphere. 2024. PMID: 38435427 Free PMC article.
106 results